Chronic Granulomatous Disease Research Services

Chronic granulomatous disease is a genetic disorder characterized by impaired granulocyte function due to an abnormality in the NADPH oxidase enzyme complex. Individuals affected by this condition suffer from recurrent infections by bacterial and fungal pathogens. Importantly, these patients also develop inflammatory complications, the most notable of which is a form of colitis that shares histological features with Crohn's disease, including granulomas and cryptitis. This colitis imposes a considerable disease burden on patients with chronic granulomatous disease, and its treatment can be challenging. Further research on chronic granulomatous colitis is needed to develop effective therapies.

Fig. 1. LC3-associated phagocytosis (LAP) and inflammation: Consequences of defective clearance of dying cells in chronic granulomatous disease. (Seger, et al., 2019)

Customized Studies for Colitis in Chronic Granulomatous Disease

At Ace Therapeutics, we are at the forefront of preclinical granulomatous colitis studies, utilizing experimental models of Crohn's disease to accelerate the development of effective therapies for this disease. The combination of our advanced, high-quality models and technologies ensures rapid turnaround time and high-quality data.

Mechanistic Studies of Colitis in Granulomatous Colitis

We offer comprehensive services to help clients analyze the pathogenesis of chronic granulomatous disease-associated colitis, opening up new opportunities for targeted drug therapy. We can conduct research in the following aspects:

• The hyper-activation of NF-ĸB and inflammasome in chronic granulomatous disease phagocytes
• Pro-inflammatory cytokine release (TNF-α, IL-1β, IL-6)
• Defective clearance of apoptotic cells
• Presentation of autoantigens

Diagnostic Development Services for Granulomatous Colitis

We can help our clients develop several diagnostic tools and materials for granulomatous colitis. These diagnostic methods help improve the ability to identify the underlying causes of granulomatous colitis.

• Developing novel biomarkers of chronic granulomatous disease-associated colitis, such as specific cytokines, chemokines, or other inflammatory mediators.
• Developing sensitive and specific assays (e.g., ELISA, multiplex platforms) to measure biomarkers in animal samples (blood, feces).
• Using genetic or genomic approaches to identify novel mutations or molecular features associated with chronic granulomatous disease-related colitis.
• Developing targeted genomic or next-generation sequencing assays to aid in the diagnosis and subtype analysis of chronic granulomatous disease-associated colitis.
• Measuring of fecal calprotectin
• Tests for stool pathogens

Drug Development Services for Granulomatous Colitis

We have extensive experience in IBD drug development. We provide reliable in vitro and animal models of to help our clients develop effective immunomodulators, biologics and stem cell therapies for chronic granulomatous disease-associated colitis.

• Drug mechanism of action studies
• Pharmacokinetics studies
• Drug efficacy and safety evaluation

Thorough preclinical study is essential to assess the efficacy of your granulomatous colitis therapy. Through rigorous evaluation and validation, Ace Therapeutics provides reliable preclinical data to give your drug candidate the best chance of success. Contact us today to begin your journey of discovery.